Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q1 2025 Earnings Presentation
28 slides from Oncoinvent Asa's earnings presentation, Apr 30, 2025
Slide 1: Oncoinvent
Oncoinvent Transforming cancer care through direct alpha therapy Targeting by proximity, brilliant in its simplicity
Slide 2: Highlights, Clinical Update, Upcoming Milestones
Highlights Clinical Update Upcoming Milestones
Slide 3: A unique radiopharmaceutical opportunity
SUMMARY A unique radiopharmaceutical opportunity 1 Targeted, non-biological, receptor independent mode of action with alpha emitter 1 2 In Phase 2 in ovarian cancer 2 3 Signals of efficacy: potential game changer in ovarian and colorectal cancers 3 4 High unmet need and limited competition 4 5 Compa
Slide 4: Recent Highlights
Recent Highlights Announced positive safety review of lead-in cohort ongoing phase 2 trial of Radspherin® in ovarian cancer patients Radspherin® Advanced to randomized part of the same trial Reported updated preliminary promising signal of efficacy at 18 months from phase 1 trial in ovarian cancer (
Slide 5: Guiding on cash
Guiding on cash As of March 31, 2025, cash and cash equivalents totalled NOK 105 Cash position million Based on the current operating plan and anticipated expenditures, including the continued development of Radspherin® in the ongoing Cash runway Phase 2 trial, Oncoinvent expects that its existing c
Slide 6: Clinical Update
Highlights Clinical Update Upcoming Milestones
Slide 7: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 7
Slide 8: The main cause of death in ovarian cancer
The main cause of death in ovarian cancer • Despite a comprehensive treatment approach, the majority of patients experience disease recurrence • Ovarian cancer rarely metastasize hematogenously, recurrences almost exclusively confined to the peritoneum • Need for improved first-line treatments that
Slide 9: New data: Continued promise of preventing disease progression
New data: Continued promise of preventing disease progression 18 months data from patients receiving 7 MBq dose vs historical recurrence rate • Ovarian cancer leads to frequent recurrences Overall recurrence rate RAD-18-001 (10 patients) despite a comprehensive treatment approach vs historical contr
Slide 10: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 10
Slide 11: Phase 2 study in ovarian cancer – enrollment started
Phase 2 study in ovarian cancer – enrollment started All 6 centers active Patients PFS pPFS • with peritoneal SoC+ Radspherin Assessment OS metastases Randomised (60 patients) every 3 months TFST Safety run-in • after neoadjuvant (6 patients) cohort 2:1 up to 24 TSST chemotherapy (90 patients) month
Slide 12: Positive safety review of lead-in cohort
Positive safety review of lead-in cohort o The phase 2 study in ovarian cancer includes patients after their first diagnosis of advanced ovarian cancer, whereas the phase 1 study included patients with recurrent ovarian cancer o Marks the first evaluation of safety and tolerability of Radspherin® •
Slide 13: Continued focus on maximizing patient recruitment
Continued focus on maximizing patient recruitment Advisory board meeting Investigator meetings Evaluate and implement further Minor protocol amendment protocol amendments Collaborate with sites and Add new countries and sites investigators to identify bottlenecks From 4Q24 to now Ongoing actions
Slide 14: Upcoming Milestones
Highlights Clinical Update Upcoming Milestones
Slide 15: Peritoneal control in colorectal cancer
Peritoneal control in colorectal cancer November 2024: 18 months data from 20 of 36 patients receiving 7 MBq dose vs historical recurrence rates “Peritoneal metastases from colorectal cancer is a Peritoneal recurrence rate condition for which there is an urgent unmet need for novel treatment options
Slide 16: Near-term significant milestones
Near-term significant milestones Final 18 months data Phase 1/2a 36 patients 7 MBq colorectal cancer Late 1H25 Final 24 months data Phase 1 10 patients 7 MBq ovarian cancer 2H25 Interim 9 months data Phase 2 Based on analysis of patients recruited by early 2026 ovarian cancer Late 2H26
Slide 17: Ovarian cancer Phase 1: No new recurrences
Ovarian cancer Phase 1: No new recurrences Radspherin® Historical control 10 % 12 months 25 % 10 % 40 % 18 months 17
Slide 18: Financial Calendar
Financial Calendar today Company update Q1-25 14 May Annual General Meeting 27 August Half-year report Q2-25 20 November Company update Q2-25
Slide 19: Questions
OnNCO invent Questions
Slide 20: Appendix
OnNCO invent Appendix
Slide 21: Peritoneal metastases - urgent need for novel treatments
Peritoneal metastases - urgent need for novel treatments • Peritoneal metastases arise from many different primary cancers • The only treatment option with curative intent is surgery, effect of systemic therapy limited • Surgery leaves behind micro-metastases giving rise to new metastases and diseas
Slide 22: Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum
UNMET MEDICAL NEED AND TREATMENT CONCEPT Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum Radspherin® How does it work? • Combining alpha-emitting 224Ra with • Administration 1-3 days post-surgery CaCO3 microparticles • Therapy with depot effect - 75% of • H
Slide 23: Radiopharmaceutical expertise at all levels
EXECUTIVE SUMMARY Radiopharmaceutical expertise at all levels Management Øystein Soug Gro Hjellum Anne-Kirsti Aksnes Kari Myren Tore Kvam Kristine Lofthus Stian Brekke Chief Executive Officer Chief Operations Officer Chief Clinical Officer Chief Medical Officer Chief Financial Officer Chief Producti
Slide 24: Oncoinvent pursues peritoneal metastases within the radiopharma landscape
EXECUTIVE SUMMARY While the radiopharma sector is largely concentrated in two indications, Oncoinvent pursues peritoneal metastases Snapshot of the Radiopharma Landscape 224Ra 212Pb 225Ac 177Lu Other Commentary metastases Peritoneal • Harnessing the advantages of radiopharmaceuticals with reduced co
Slide 25: Pipeline in one product - broad clinical application
UNMET MEDICAL NEED AND TREATMENT CONCEPT Pipeline in one product - broad clinical application Extraperitoneal Intraperitoneal origin origin Lung cancer Cholangiocarcinoma Breast cancer Gastric cancer • Peritoneal metastases arise from many Malignant melanoma Pancreatic cancer different cancers Kidne
Slide 26: Microparticle retention limits off-target organ exposure
PHASE 1/2A RESULTS Microparticle retention limits off-target organ exposure • Absorbed doses below 1 Gy* for all organs measured • Highest absorbed doses to organs at risk for osteogenic cells, followed by liver, bone marrow and kidneys • No signs of hematological, kidney or liver toxicity observed
Slide 27: Radspherin® - solid multilayer intellectual property protection
INTELLECTUAL PROPERTY Radspherin® - solid multilayer intellectual property protection Radspherin® composition of matter & use • Granted in US, EU, China, Japan and additional countries • Patent expiry 2035 (2036 in some countries) with an option for 5 years extension Radspherin® formulation • Filed
Slide 28: In-house production at GMP facility
MANUFACTURING AND SUPPLY In-house production at GMP facility Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house Current GMP facility supplies phase 2, outsourcing and scale-up required for phase